Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival gains in HR+/HER2– MBC trials yet to be seen in real world

Key clinical point: Survival rates for the most common form of metastatic breast cancer did not change over a decade.

Major finding: Median overall survival after diagnosis was 2.0 years, and did not differ with time.

Study details: Retrospective analysis of data on 2,197 patients with HR+/HER2– metastatic breast cancer treated in British Columbia.

Disclosures: No specific study funding was disclosed. No authors disclosed potential conflicts of interest.


Le D et al. Cancer 2019 Nov 21. doi: 10.1002/cncr.32631.